» Articles » PMID: 17222357

Noonan Syndrome

Overview
Publisher Biomed Central
Specialty General Medicine
Date 2007 Jan 16
PMID 17222357
Citations 116
Authors
Affiliations
Soon will be listed here.
Abstract

Noonan Syndrome (NS) is characterised by short stature, typical facial dysmorphology and congenital heart defects. The incidence of NS is estimated to be between 1:1000 and 1:2500 live births. The main facial features of NS are hypertelorism with down-slanting palpebral fissures, ptosis and low-set posteriorly rotated ears with a thickened helix. The cardiovascular defects most commonly associated with this condition are pulmonary stenosis and hypertrophic cardiomyopathy. Other associated features are webbed neck, chest deformity, mild intellectual deficit, cryptorchidism, poor feeding in infancy, bleeding tendency and lymphatic dysplasias. The syndrome is transmitted as an autosomal dominant trait. In approximately 50% of cases, the disease is caused by missense mutations in the PTPN11 gene on chromosome 12, resulting in a gain of function of the non-receptor protein tyrosine phosphatase SHP-2 protein. Recently, mutations in the KRAS gene have been identified in a small proportion of patients with NS. A DNA test for mutation analysis can be carried out on blood, chorionic villi and amniotic fluid samples. NS should be considered in all foetuses with polyhydramnion, pleural effusions, oedema and increased nuchal fluid with a normal karyotype. With special care and counselling, the majority of children with NS will grow up and function normally in the adult world. Management should address feeding problems in early childhood, evaluation of cardiac function and assessment of growth and motor development. Physiotherapy and/or speech therapy should be offered if indicated. A complete eye examination and hearing evaluation should be performed during the first few years of schooling. Preoperative coagulation studies are indicated. Signs and symptoms lessen with age and most adults with NS do not require special medical care.

Citing Articles

Trametinib as a targeted treatment in cardiac and lymphatic presentations of Noonan syndrome.

De Brouchoven I, Lorand J, Bofferding L, Sorlin A, Van Damme A, Danhaive O Front Pediatr. 2025; 13:1475143.

PMID: 40041314 PMC: 11876372. DOI: 10.3389/fped.2025.1475143.


Health outcomes and drug utilisation in children with Noonan syndrome: a European cohort study.

Santoro M, Barisic I, Coi A, Tan J, Garne E, Loane M Orphanet J Rare Dis. 2025; 20(1):76.

PMID: 39962527 PMC: 11834245. DOI: 10.1186/s13023-025-03594-7.


Portraying the full picture of Neurofibromatosis-Noonan syndrome: a systematic review of literature.

Trimeche O, Sakka R, Hajji E, Missaoui A, Amor B, Bayar I J Med Genet. 2024; 62(2):109-116.

PMID: 39643432 PMC: 11877060. DOI: 10.1136/jmg-2024-110253.


Non-malignant features of cancer predisposition syndromes manifesting in childhood and adolescence: a guide for the general pediatrician.

Kuhlen M, Weins A, Stadler N, Angelova-Toshkina D, Fruhwald M World J Pediatr. 2024; 21(2):131-148.

PMID: 39641826 PMC: 11885337. DOI: 10.1007/s12519-024-00853-8.


Discovery of Novel Biomarkers with Extended Non-Coding RNA Interactor Networks from Genetic and Protein Biomarkers.

Jezernik G, Glavac D, Skok P, Krusic M, Potocnik U, Gorenjak M Int J Mol Sci. 2024; 25(18).

PMID: 39337694 PMC: 11432684. DOI: 10.3390/ijms251810210.


References
1.
Reynolds D, Rubin S, Fox J, Kodsi S . Ocular manifestations of Noonan syndrome in the pediatric patient. J AAPOS. 2004; 8(3):282-3. DOI: 10.1016/j.jaapos.2003.12.011. View

2.
van der Burgt I, Brunner H . Genetic heterogeneity in Noonan syndrome: evidence for an autosomal recessive form. Am J Med Genet. 2000; 94(1):46-51. DOI: 10.1002/1096-8628(20000904)94:1<46::aid-ajmg10>3.0.co;2-i. View

3.
PIERINI D, Pierini A . Keratosis pilaris atrophicans faciei (ulerythema ophryogenes): a cutaneous marker in the Noonan syndrome. Br J Dermatol. 1979; 100(4):409-16. DOI: 10.1111/j.1365-2133.1979.tb01641.x. View

4.
Theintz G, Savage M . Growth and pubertal development in five boys with Noonan's syndrome. Arch Dis Child. 1982; 57(1):13-7. PMC: 2863270. View

5.
Noordam C, van der Burgt I, Sengers R, Delemarre-van de Waal H, Otten B . Growth hormone treatment in children with Noonan's syndrome: four year results of a partly controlled trial. Acta Paediatr. 2001; 90(8):889-94. View